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1. Introduction 
Bladder cancer is one of the most common cancers in the world. In 2006, there were about 
61,240 diagnosed cases of bladder cancer and approximately 13,060 deaths attributable to 
this disease, being the prevalence estimated worldwide more than 1,000,000 patients (Jemal 
et al., 2006; Lerner, 2005). Taking into account that its incidence seems to be increasing, 
bladder cancer is clearly a significant public health issue around the world. Thus, it is 
necessary to intensify research on this topic.  
Urinary bladder cancer originates mainly from epithelial cells of the urothelium (Lopez-
Beltran et al., 2004; Montironi et al., 2005). When initially diagnosed, most bladder cancers 
(about 70%) do not present muscle invasion, and are thus known as non-muscle invasive 
bladder cancer (pTa and pT1). In these cases, a simple transurethral resection is sufficient to 
remove the tumor. However, some patients experience recurrence or even tumor 
progression.  The progression of the tumor involves invasion of tumor cells, which penetrate 
deeper layers of the bladder such as the detrusor muscle (pT2), perivesical tissue (pT3) and 
extravesical organs (pT4) (Figure 1). Since this progression threatens the patient's life, more 
aggressive therapies are necessary (Sobin et al., 1997).  
Intensive research in bladder cancer, as well as that in most tumors, is being carried out to 
elucidate the reason for the appearance of tumors, and to find out which factors are 
involved in their development and which are related to the tumor progression process. 
These investigations, which provide insights into the biology of the tumor, are essential for 
the implementation of new therapeutic and/or preventive modalities (Bhattacharya et al., 
2010; Zhang et al., 2011). 
Research on basic science is focused on the mechanisms that lead cells towards 
transformation and development of cancer, using simple experimental models where it is 
easier to interpret the results. Cell culture techniques are widely used to study different 
oncological processes. The cell culture is the growth of any cell type, usually tumor cells, in 
with nutrient-containing solutions. The cells grow attached to the plastic surface, forming a 
monolayer, usually in a two-dimensional way. This technique allows studying processes 
such as mutagenesis, invasion, migration, and production of proteolytic enzymes. Although 
cell culture is a very important tool, it has certain limitations. Many biological processes 
depend on the three-dimensional architecture. In addition, monolayer culture is usually 
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restricted to a single or at most two cell types. In contrast, tumors are complex and consist of 
tumor cells and other cell types such as stroma and immune cells that interact to either 
promote or inhibit tumor growth. To overcome these limitations, it is necessary to use three-
dimensional models, such as tissue or organ cultures (Varley et al., 2011).  
 
 
Fig. 1. A: Histology of a normal bladder from a C57BL/6J mouse (Hematoxylin- eosin).  
B: Scheme of the invasion status of bladder tumors. Non-muscle invasive tumors pTa when 
are confined to epithelium, and pT1 when  penetrating into the chorion. Invasive tumors 
when penetrate deeper layers of the bladder such as the detrusor muscle (pT2), perivesical 
tissue (T3) and extravesical organs (pT4). 
To corroborate in vitro results, the next step in the investigation is the assay in a living 
organism. Animal models are important tools which allow studying the mechanisms of 
carcinogenesis as well as carrying out preclinical studies of new therapeutic modalities. It is 
important to design a model as similar to human disease as possible, so that observations 
can be readily transferred to clinical studies.  
2. General characteristics of animal models 
Animal models constitute the essential link between cell-based experiments and the 
translation of novel agents into human patients with cancer. They are used to study the 
development and progression of diseases and to test new treatments before they are 
provided to humans. Therefore, models should be as close to human pathology as possible. 
In evolutionary biological terms, large animals have more similarity to humans. However, 
the most widely used animal models are rodents, in particular mice and rats. Although 
imperfect in their translatability into clinical efficacy, these animals have the advantage that 
they reproduce easily in short time, are easy to maintain with low cost, and can be 
manipulated genetically, thus remaining a critical tool in bladder cancer research. 
Models allow researchers to study different characteristics of the tumor biology such as 
tumor growth, latency, growth rate, invasion and metastasis. Studies of carcinogenic 
substances or prevention of carcinogenesis may be carried out in animal models. Also, 
analysis of the response to cytotoxicity and immunotherapy treatments can be performed 
(Bhattacharya et al., 2010; Takeuchi et al., 2011; Zhang et al., 2011). 
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According to the site of tumor inoculation, models are classified as heterotopic or orthotopic 
(see points 2.1.4 and 2.1.5.). In addition, depending on the species in which the tumor cell 
lines are inoculated, models may be xenogeneic or syngeneic models (see below). 
2.1 Mouse models in bladder cancer 
2.1.1 Xenogeneic models  
Animals with transplanted human cancers are called xenogeneic or xenograft models. Nude 
mice are commonly used to inoculate human tumor fragments or bladder cancer cells. These 
mice have a spontaneous mutation in chromosome 11 named nude (nu), which gives certain 
phenotypic and functional changes. Homozygous nude mice show absence of hair, the 
feature that gave the name to the mutation. However, a few years after the appearance of 
the mutation, it was found that nude mice do not have a functional thymus. As a 
consequence, these animals have a low number of mature T lymphocytes, which allows 
them to accept xenograft transplantation. This feature of nude mice has contributed to the 
development of research in cancer, making these animal models useful to study the in vivo 
growth of human tumors and human cancer cell lines in which the efficacy of therapeutic 
agents such as monoclonal antibodies, cytotoxic drugs and radiotherapy can be tested. 
Below are a few examples of the relevant experiments in bladder cancer therapy using 
xenograft models. 
One of the main features of tumors is their capacity to grow uncontrollably, invading the 
surrounding tissue, inducing neoformation of blood (angiogenesis) and lymphatic vessels 
and spreading in the body, forming secondary tumors or metastasis. In most cases, the 
death of patients with bladder cancer is due to the generation of metastasis. Angiogenesis, 
which is intricately involved in growth and metastasis and is in fact a prerequisite for these 
processes (Fidler, 1990; Folkman, 1986), is regulated by a fine balance between stimulatory 
and inhibitory factors produced by the tumor and the surrounding stroma (Liotta et al., 
1991). Bladder tumors produce high levels of several stimulatory factors, being the vascular 
endothelial growth factor (VEGF) overexpressed in bladder cancer (Crew et al., 1997; O'Brien 
et al., 1995). The action of this factor is mediated by its membrane receptor (VEGFR). Both 
VEGF and VEGFR are considered as important therapeutic targets. Some papers have 
studied the effects of a neutralizing monoclonal antibody targeted at murine VEGFR by 
using a xenograft model.  In combination with cytotoxic compounds, such as paclitaxel, this 
monoclonal antibody impairs tumor growth and angiogenesis and. thus prevents metastatic 
spread and prolongs mouse survival (Davis et al., 2004; Inoue et al., 2000).  
Xenograft models have also been used in radiopharmaceutical studies (Pfost et al., 2009). 
Pfost et al. coupled monoclonal antibodies that recognize epidermal growth factor receptors 
on bladder cancer cells with 213Bi, a radioactive alpha particle emitter, and found that 
therapy with 0.37 MBq of radiation after tumor cell inoculation in the bladder of nude mice 
results in higher survival of mice when compared with conventional treatment with 
Mitomycin C. These authors were also able to show that Mitomycin C produces 
nephrotoxicity, whereas 213Bi-anti-EGFR-mAb treatment showed no signs of nephrotoxicity. 
These results suggest that radioimmunotherapy using intravesically instilled 213Bi-anti-
EGFR-mAb is a promising option for the treatment of bladder cancer in patients. 
Xenogeneic models have also been used for the detection of growth and metastasis spread 
by bioluminescence techniques (Hadaschik et al., 2007). To monitor tumor growth and 
therapeutic efficacy, noninvasive imaging concepts are preferable. For that purpose, tumor 
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cells are stably transfected with genes coding for fluorescent proteins (Tanaka et al., 2003) or 
enzymes catalyzing bioluminescence (Hadaschik et al., 2007), allowing for the continuous 
visualization of tumor development after intravesical instillation of tumor cells. 
Although, as described above, xenograft models are important tools to study the behavior of 
human tumors in vivo, they also have an important limitation: they are immunodeficient. 
This makes this animal model not suitable to study interactions between the host immune 
system and the tumor. Furthermore, xenograft models are useless for research on the 
biological mechanisms related to carcinogenesis or on the possible compounds able to 
prevent carcinogenesis. In contrast, syngeneic animal models are more appropriate to 
approach these issues.  
2.1.2 Syngeneic models 
Syngeneic models include the appearance of spontaneous tumors, induction of tumors by 
chemical carcinogens, and inoculation of tumor cells in mice genetically identical to those in 
which tumors were developed. All of them are useful for studies in which the host-tumor 
interaction must be taken into account. 
Immunotherapy  
In patients, non-muscle invasive bladder cancers are usually managed with transurethral 
resection followed by the intravesical administration of Bacillus Calmette-Guerin (BCG). 
This immune therapy has been used without modification since 1976 (Morales et al., 1976). 
In addition to the direct anti-tumor effect (Sandes et al., 2007), it is widely recognized that 
intravesical BCG therapy is more potent in preventing tumor recurrence than any other 
intravesical chemotherapy (Sylvester, 2009). However, about 20% of patients either fail to 
respond initially or relapse within the first five years of treatment (Smaldone et al., 2009). 
The exact mechanisms of BCG action have not been completely elucidated yet. However, it 
is known that BCG generates a local immunological reaction with activation of immune cells 
as well as secretion of cytokines involving Th1 cell cytotoxicity (Riemensberger et al., 2002). 
To investigate the immune mechanisms by which BCG prevents bladder tumor recurrence 
and progression as well as the mechanisms of immune suppression to explain the lack of 
effectiveness of BCG observed in some patients, animal models with a competent immune 
system are needed. Syngeneic mouse bladder cancer models have thus been used for this 
purpose.  
Animal models using subcutaneous or orthotopic inoculation of bladder cancer cell lines 
are being designed to study potential therapies to reverse these immune suppressive 
mechanisms. Mangsbo et al. have studied a syngeneic model by inoculating MB49 bladder 
cancer cell lines in the subcutis of C57BL/6J mice. This experimental model closely 
mimicks human bladder cancer, because MB49 cells express negative regulatory proteins 
of the immune response (Inman et al., 2007; Nakanishi et al., 2007). Among others, the 
programmed death ligand 1 (PD-L1) and the cytotoxicity T lymphocyte antigen-4 (CTLA-
4) render T regulatory cells (Tregs) that can oppose to BCG immunotherapy. Antibodies 
able to block PD-L1 and CTLA-4 administered intratumorally improves long-term 
survival and leads to increased levels of tumor-reactive T cells and decreased numbers of 
Tregs at the tumor site. Therefore, this experimental model has allowed an approach to 
the understanding of immune suppression during immune therapy with BCG and 
represents a new therapeutic option in the treatment of bladder cancer (Mangsbo et al., 
2010). 
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It is known that BCG is neither free of mild or intermediate side effects such as fever and 
granulomatous prostatitis nor of severe side effects such as pneumonitis, hepatitis and BCG 
sepsis (DeHaven et al., 1992). To avoid such unfavorable events, it is necessary to develop a 
more active and less toxic immunotherapeutic agent. A mouse syngeneic model using 
subcutaneous inoculation of MBT2 bladder cancer cell lines has been used to evaluate the 
effectiveness of liposomes containing walls from BCG bacteria as immune therapy. With this 
experimental design, Joraku et al. have demonstrated inhibition of tumor growth with 
increased immunity. Thus, this non-live bacterial agent may contribute to providing a more 
active and less toxic tool as a substitute for live BCG in immunotherapy (Joraku et al., 2009). 
Besides the study of the immune mechanism, other studies involving the tumor-host 
interaction have used syngeneic models. For example, in our laboratory, we have 
evaluated the mechanism of action of BCG using animals inoculated subcutaneously with 
MB49 bladder cancer cells, and found that macrophages from tumor-bearing mice treated 
with BCG intratumorally were able to produce soluble factors including fibroblast growth 
factor-2 (FGF-2), which induces fibroblast proliferation. We also found that in vivo BCG 
therapy reduces tumor growth with a concomitant increase in collagen deposition and 
expression of alpha-smooth muscle actin and FGF-2. These results suggest that tissue 
repair mechanisms similar to healing are involved in BCG immunotherapy of bladder 
cancer (Lodillinsky et al., 2010). 
Carcinogenesis and chemo-prevention  
Bladder cancer is a candidate for chemo-prevention intervention for several reasons. In the 
first place, bladder cancer patients present successive recurrences that must be prevented. 
Also, in addition to genetic susceptibility, this cancer is closely related to exposure to 
environmental contaminants, including cigarette smoking, which implies the constant 
contact of carcinogenetic substances with the urothelium. 
Animal models are widely used to select chemical synthesis products, purified natural 
products or even mixtures of natural products with potential to prevent tumor 
development, which can then be used in clinical trials. The idea is to use organ-specific 
animal models to determine which agents are likely to be helpful in preventing specific 
forms of cancer. These animal models can be obtained by chemical induction, spontaneous 
occurrence or use of transgenic animals.  
To be useful, animal models must meet several characteristics. The model should be of 
clinical relevance, not only in terms of organ specificity but also in terms of the histology 
and the genetic abnormalities. Furthermore, premalignant lesions should be developed 
with genetic and histological features as similar as possible to those observed in the 
development of human cancer. In addition, the model must be consistent in generating 
tumors in a significant number of animals in a reasonable period. Finally, the model must 
be predictive in terms of clinical efficacy, i.e. that the positive or negative results obtained 
in the animal model should later correlate with positive and negative results in human 
trials (Steele et al., 2010). 
One of most useful models is the induction of bladder cancer in mice and rats with 
hydroxybutyl(butyl)nitrosamine (OH-BBN). This carcinogen compound induces 
premalignant lesions that progress to transitional bladder tumors, and in little proportion of 
squamous tumors (Grubbs et al., 2000). Recent studies by Lu et al. have compared bladder 
tumors in rats and mice induced by OH-BBN with human bladder tumors, using a global 
gene expression approach cross-species analysis, and shown the similarity between this 
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animal model and bladder cancer in humans. These genes are likely to have conserved 
functions contributing to bladder carcinogenesis. To strengthen this analysis, these authors 
studied the molecular pathway commonly activated in both human and rodent bladder 
cancer and found a number of pathways that affect the cell cycle, HIF-1 and MYC 
expression, and regulation of apoptosis in both rodent and human bladder cancer. Also, 
they compared expression changes at mRNA and protein levels in the rat model and 
identified several genes/proteins exhibiting concordant changes in human bladder tumors. 
They concluded that rodent models (in OH-BBN-treated B6D2F1 mice and Fischer-344 rats) 
of bladder cancer accurately represent the clinical situation to an extent that will allow 
successful miming of target genes, showing that these models are powerful tools for 
chemoprevention research (Lu et al., 2010). Using this experimental model, it has been 
demonstrated that NSAIDs (such as indomethacin, naproxen, NO-naproxen, and celecoxib), 
various EGFR inhibitors, and purified natural compounds (such as tea polyphenols and 
sulforaphane) have striking efficacy to prevent bladder tumor development (Ding et al., 
2010; Grubbs et al., 2000; Lubet et al., 2005; Steele et al., 2009; Yao et al., 2004). 
Two disadvantages inherent in these models are the long experimental times (usually 
periods between 8 to 12 months) and the occupational exposure of workers. To avoid the 
use of carcinogens, knockout or transgenic mouse models can be used. These models are 
used in chemoprevention trials as well as in studies on the relevance of  each gene in tumor 
development. 
2.1.3 Transgenic models 
Activation of oncogenes or inactivation of tumor suppressors in the urothelium is 
considered critical for the development of urothelial cancer. Transgenic mice have proven to 
be powerful tools to unravel the mechanisms of carcinogenesis and to understand the 
molecular basis of the disease. Transgenic mice are a particular case of syngeneic models, 
which are genetically modified to study the importance of a particular gene in cancer 
development and progression. Knockout mice, which are genetically modified mice, can be 
used to study the effect on the deficiency of a particular gene. 
Alterations in the suppressor genes RB1 and p53 as well as the activation of oncogenes such 
as Ha-ras are commonly found in human urothelial tumors. Transgenic mice with 
alterations in these genes have been designed. By way of example, we will next describe 
some of the models developed and the conclusions that have been reached. 
Mouse embryos lacking the retinoblastoma (Rb) gene die 14 days into gestation and mice 
lacking the p53 gene succumb to thymic lymphomas at seven months of age. So, the role of 
these genes in the analysis of tumorigenesis was delayed until conditional transgenic mice 
were developed. These models achieve the loss of gene function only in a particular tissue. 
The specific urothelium knockout system was developed using the Cre/loxP strategy. 
Transgenic mouse lines in which a 3.6-kb mouse uroplakin II promoter is used to drive the 
expression of Cre recombinase (Cre) have been generated (Mo et al., 2005). The use of this 
model has allowed understanding the role of antitumor genes such as RB, p53 and PTEN in 
bladder carcinogenesis (Ahmad et al., 2011; Ayala de la Pena et al., 2011; He et al., 2009). 
Conditional inactivation of both RB1 alleles in the mouse urothelium instead of accelerate 
urothelial proliferation, profoundly activated the p53 pathway, leading to extensive 
apoptosis in urothelial cells. Thus, pRb loss triggers fail-safe mechanisms whereby urothelial 
cells can evade tumorigenesis. Additional loss of p53 in pRb-deficient urothelial cells can 
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remove these p53-dependent tumor barriers, resulting in hyperplasia or umbrella cell 
nuclear atypia. Also, superficial papillary bladder tumors of low-grade (rare occurrence) but 
not invasive carcinomas have been detected. Furthermore, mice deficient in both pRb and 
p53 are highly susceptible to carcinogen exposure, developing invasive carcinomas that 
resemble human bladder cancer (He et al., 2009). Another transgenic mouse with 
inactivation of the tumor suppressor p53 has been obtained by expression of SV40 large T 
antigen, directed to the urothelium with the specific promoter uroplakin-II. In the same way 
as in the transgenic mice described above, this construction has allowed demonstrating that 
the elimination of p53 alone is not sufficient for the generation of bladder tumor (Ayala de la 
Pena et al., 2011). The function of proto-oncogene activation has been assessed by using Ha-
ras trangenic mice (Zhang et al., 2001). 
Transgenic mice with compromised immune systems have also been developed. Mice 
knockout to IFN gamma (IFNɣ -/-), interleukins 17, 12 and 23  (IL-17 -/-; IL-12-/- and IL-23 
-/-), among others, are being used to understand how different components of the immune 
system either promote or inhibit the development of bladder tumors (Kortylewski et al., 
2009; Langowski et al., 2006; Wang et al., 2009). 
In both syngeneic and xenogeneic models, tumors can grow in heterotopic or orthotopic 
sites. Below we describe the advantages and disadvantages of both modalities. 
2.1.4 Heterotopic tumor growth 
This site of inoculation refers to the growth of a tumor in a site different from its target 
organs, generally using subcutaneous inoculation. This approach is advantageous in cases 
where the orthotopic inoculation (see below) is complex such as in bladder, kidney, and 
bowels. Tumor inoculation is simple and can be carried out by an operator with minimum 
training. Furthermore, the tumor can be easily detected and the tumor evolution can be 
easily assessed by using palpation of the skin and measurement with a caliper, respectively. 
To assess tumor growth, at least two perpendicular diameters, the larger diameter (D) and 
the smaller diameter (d), must be measured. Some researchers also measure depth (Figure 
2). However, the latter is difficult to determine and generally produces large errors. Tumor 
size can be calculated from these data, using various formulas such as geometric mean 
((Dxd)1/2 expressed in millimeters), arithmetic average (Dxd/2 expressed in mm2), or volume 
of the ellipsoid (4/3 π Dxd2, expressed mm3). Not all tumors grow in the same way; some of 
them are more compact, whereas others develop necrosis. Therefore, to choose the most 
appropriate formula for each tumor, it is first necessary to validate the formula that best fits, 
when compared with tumor weight. 
The main disadvantage of the heterotopic model is the fact that an anatomic site other than 
an orthotopic site can differentially develop tumor growth. The tumorigenesis and 
metastatic potential of tumors depend not only on the characteristics of the tumor cells, but 
also on the tumor environment and therefore on the site of injection. Human tumors can be 
formed by different cell subpopulations with varying ability to metastasize and 
susceptibility to treatment, depending on the site of inoculation (Fidler, 1986). It has been 
observed that subcutaneous inoculation of murine MB49 bladder cancer cell lines induces 
lung metastases,  and that inoculation of these cells in the bladder does not (Lodillinsky et 
al., 2009). Similar observations have been made for human tumors using 253J B-V cells 
(Black et al., 2007). After 28 days of tumor growth either in the bladder or in the subcutis, 
Black et al. were able to determine that the tumor size was similar in both sites, but that only 
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tumors growing orthotopically in the bladder developed metastasis to lymph nodes and 
lungs. The orthotopic tumors, as compared to the subcutaneous tumors, have an increased 
microvessel density, increase in growth factors expression and proteolytic enzyme activity. 
Therefore, models of orthotopic growth are more appropriate for studies related to 
metastasis dissemination or response to any treatment. 
 
 
Fig. 2. Heterotopic tumor growth: MB49 bladder cancer cells growing in the subcutis of 
C57BL/6J mice.  
There are some heterotopic models such as inoculation into the tail vein or the left ventricle 
of the heart which have been widely used to evaluate the process of extravasations and 
colonization in the lung or bone, respectively (Growcott, 2009; Wu et al., 2010). Although 
very used, these models consider only a limited aspect of the metastatic process (Figure 3).  
 
 
Fig. 3. Lung metastases: inoculation of MB49 (panel A) or MB49-I (panel B) bladder cancer 
cell lines into the tail vein induces lung metastasis. The lungs are colored in black by 
intratracheal inoculation of Indian ink. Metastases are seen in yellow by the stain and 
Bouin’s fixative solution. 
2.1.5 Orthotopic tumor growth 
Growth in the target organ allows for better analysis of the interaction between the host and 
the tumor. When tumors are chemically induced, the carcinogen is chosen such that the 
tumor develops in the desired organ. Thus, tumor growth occurs in the orthotopic site. 
However, in the case that the tumor is generated by inoculation of a tumor fragment or 
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tumor cell lines, the orthotopic inoculation is not always easy to perform. However, this 
difficulty must be overcome since the results obtained with heterotopic models are not 
always easy translated into clinical trials.  
As previously mentioned, there are examples showing that different results are observed 
when the tumor is inoculated subcutaneously or orthotopically in the bladder. In studies of 
chemoprevention, inhibition of bladder cancer development by allyl isothiocyanate was 
detected for tumors growing orthotopically but not in the subcutis (Bhattacharya et al., 
2010). Furthermore, as described in the previous section, considerable variation has been 
detected between the two models in assays of immunotherapy, angiogenesis, invasion and 
metastatic spread, among others. Taking these limitations into account, to achieve a correct 
interpretation of results and a translatable preclinical model, it is necessary to inoculate the 
tumor in the bladder.  
Inoculation into the bladder requires a qualified technician. Mice must first be anesthetized 
and subsequently, a 24-gauge Teflon i.v. catheter must be inserted through the urethra into 
the bladder using an inert lubricant to avoid discomfort in mice. For successful implantation 
of the bladder tumor cells, the urothelium must first be damaged. There are different 
techniques to induce such damage in the bladder. One of them involves the use of 
hydrochloric acid (0.1 ml 0.1 M HCl for 15 minutes) and subsequent neutralization with 
alkali and extensive washing with saline (Zhang et al., 2011). Another technique involves 
instillation of a solution of silver nitrate (NO3Ag ) (Chade et al., 2008). Both forms of injury 
allow the generation of tumors uniformly distributed in the bladder. The inoculation of 
MB49 tumor cells (1x105 to 5x105) in syngeneic mice generates superficial tumors in about 7 
to 15 days. Other techniques, using polylysine instillation, intramurally inoculation via 
laparotomy, or electro cauterization of the urothelium, are also used (Black et al., 2010). 
Cauterization of the bladder mimics transurethral resection of bladder tumor and therefore 
should facilitate adherence of instilled tumor cells to the bladder wall. The method was 
designed by Gunther et al. for the inoculation of MB49 cells in syngeneic mice (Gunther et 
al., 1999). However, it is also used for inoculation of cells from human bladder tumors in 
nude mice (Pfost et al., 2009). The technique involves the insertion of a guiding wire into the 
bladder of a mouse positioned dorsally on the ground plate of the cautery unit via the teflon 
catheter. When it is verified that the wire touches the bladder wall, the wire is attached to 
the cautery unit, and a monopolar coagulation mode is applied for 2 seconds at the lowest 
level (7 W). Then, via the same catheter, an appropriate number of tumor cells are 
inoculated and should remain in the bladder for at least 30 minutes (Figure 4A). 
Another difficulty to be overcome is the determination of the evolution of bladder tumor 
growth. Unlike what happens in the case of a subcutaneous tumor growth, where its size 
can be easily determine at different times of evolution, the growth evolution in the bladder 
is more uncertain. However, hematuria is the hallmark of tumor presence (Figure 4B). Mice 
with 1x104 or 1x105 MB49 cell lines, inoculated by electrocautery, present hematuria about 
15 or 9 days post-inoculation, respectively (Lodillinsky et al., 2009). Inoculation of 5x103 cells 
in the bladder previously treated with NO3Ag generates hematuria in all mice about 7 days 
after tumor implantation (Chade et al., 2008). Palpation of the bladder may give an idea of 
the extent of the tumor, but it is difficult to carry out because the bladder is retropubic. Also, 
in some cases, palpation could be given a wrong interpretation. When there is an 
obstruction of the urethra by blood clots, the bladder is greatly enlarged as a product of the 
accumulation of urine, and may thus lead to a wrong estimate of the extension of the tumor 
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(Figure 4C and D). Therefore, in these cases, the true evaluation of tumor size can be 
obtained at the end of the experiment, either by measuring the bladder with a caliper or by 
determining its weight (Figure 4E and F). Experiments of this type, also called end-point, 
have the disadvantage that they focus only on one measure of tumor size and not on its 
evolution throughout the experiment. This problem will soon be overcome by the design of 
non-invasive diagnostic equipment for small animals, similar to those used in medical 
practice in humans, such as ultrasound-doppler, infrared (IR) or bioluminescence imaging. 
By way of example, ultrasound-Doppler sagittal images have been used to evaluate 
angiogenesis in a mouse bladder cancer model (Sugano et al., 2011). Also, bladder cancer 
cells that have been engineered to express certain proteins that emit fluorescence are being 
used in bioluminescence detection of tumor development (Black et al., 2010). 
 
 
Fig. 4. Bladder tumor growth: A) orthotopic inoculation: after cauterization and inoculation 
of the appropriate number of tumor cells, mice should remain upside-down for at least 30 
minutes  so that cells can adhere to the bladder epithelium. B) Hematuria is the hallmark of 
tumor presence. C) Mouse with bladder tumor. D) Mouse with bladder containing urine but 
without tumor. E) Two bladders with tumor. F) Bladders from normal mice.  
2.2 Mouse bladder cancer model for study of invasion and metastasis 
2.2.1 Invasion and metastasis 
The process of tumor invasion and metastasis is the most devastating stage of neoplastic 
disease and worsens prognosis of cancer patients. Adverse effects of systemic anti-tumor 
therapy and organ failure invaded with metastatic tissue are the leading causes of death in 
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these patients (Steeg et al., 2006). It is currently accepted that tumors have a clonal origin, 
which means that they are derived from a single cell. The high proliferative capacity, 
coupled with the genetic instability of tumor cells, generates new mutations, and thus the 
generation of other cell populations conferring tumor heterogeneity. This is considered part 
of an evolutionary process of genetic and epigenetic changes that allow some of the primary 
tumor cells acquire an adaptive advantage to migrate and colonize new environments. 
However, new findings have shown the possibility of a parallel development of cells 
capable of early metastatic spread. This parallel progression model urges to review the 
current diagnostic and treatment (Klein et al. 2009).  
The local invasion process that gives rise to metastatic spread is a multi-step event called 
metastatic cascade. This is a phenomenon with low efficiency, indicating that only a few of 
the cells that emerge from the primary tumor are able to generate metastases. 
Initially, tumor cells release proteolytic enzymes, such as MMPs and cathepsins, which 
degrade the extracellular components of basement membrane, thereby creating gaps that 
allow the invasion of the underlying connective tissue. The tumor cells migrate through the 
extracellular matrix and some may penetrate the lymphatic and blood capillaries, a 
phenomenon knows as intravasation. Once in the bloodstream, cells that manage to survive 
must leave the vessel (extravasation) into different organs (Figure 5). When the 
microenvironment of the target organ is appropriate, colonizing tumor cells can form 
metastases. 
 
 
Fig. 5. During the metastatic cascade, tumor cells undergo genotypic and phenotypic 
changes that increase their capacity for invasion and migration. Some tumor cells are 
capable of degrading the basal membrane and migrating through connective tissue. Cells 
from connective tissue, such as macrophages and fibroblasts, through the release of growth 
factors, cytokines and proteolytic enzymes, can enhance the invasive behavior of tumor 
cells. 
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2.2.2 Metastogenes 
The study of gene expression in primary tumor cells and metastatic cells has begun to lift 
the veil that prevented the understanding of the complex process of metastasis. These 
studies have identified a set of genes involved in the development of metastasis, called 
"metastogenic genes". Although there may be some overlap, these genes have been classified 
into three categories: a) initiation genes, b) progression genes and c) virulence genes 
(Nguyen et al., 2007).  
Initiation genes are associated with the processes of invasion, angiogenesis and epithelial-
mesenchymal transition (EMT). Since during invasion the migration of cells is an important 
step, genes encoding for GTPases involved in cytoskeleton remodeling such as RhoC have 
been included in this category. Among those involved in angiogenesis are those encoding 
the vascular endothelium growth factor, and matrix metalloproteinase 9 (MMP9). EMT 
allows changes that give advantages in terms of migration and invasion. Certain genes that 
encode for transcription factors associated with this transition such as TWIST1 are also 
included in this group. 
Progression genes are linked to the negative regulation of the immune response, vascular 
remodeling and extravasations. Examples are the gene coding for cyclooxygenase 2 (COX-
2), matrix metalloproteinase 1 (MMP-1) and angiopoietin-like 4 (ANGPTL4), among others.  
Finally, virulence genes are those which give the tumor cell an adaptive advantage to 
survive within an organ-specific microenvironment (Chiang et al., 2008). Among them are 
intercellular signaling molecules such as cytokines and interleukins (CXCR4 and IL-11), 
molecules of the family of tumor necrosis factor (TNF) that are associated with bone 
metabolism (RANKL) and mediators of the angiogenic process such as the Endothelin-1. 
Recent findings have identified the expression pattern characteristic of primary tumor gene, 
which is similar to a genetic signature that predicts the metastatic potential of the tumor 
(Bertucci et al., 2007, Van't Veer et al., 2002). This implies that the genetic profile expressed in 
metastases in specific organs is not always the same. Different groups of genes allow tumor 
cells to interact with stromal cells of the target organ. For example, the genes involved in 
breast cancer metastasis to bone are different from those involved in metastasis to the lung. 
This knowledge would allow the development of therapeutic strategies specific for each 
gene expression pattern or "signature " of a metastasis. 
2.2.3 Epithelial-mesenchymal transition 
During the invasion process, the tumor cells show a phenotypic change called epithelial-
mesenchymal transition (EMT), which is characterized by a morphological change that is 
due to a genetic reprogramming process which normally occurs during embryonic 
development and tissue repair such as scarring (Peinado et al., 2007). This reprogramming 
involves the expression of a group of transcriptional repressors (Zeb-1 and 2, Twist, Snail 
and Slug) that recruit histone deacetylases, controlling the expression of genes associated 
with the epithelial phenotype. An example of this is the decreased expression of E-cadherin, 
which leads to a loss of homotypic adhesion. Certain cytokines of the family of transforming 
growth factor beta (TGFbeta) and bone morphogenetic protein (BMP) are responsible for 
increasing the expression of these repressors (McConkey et al., 2009).  
Simultaneously with an underexpression of proteins of the epithelial phenotype, an 
overexpression of molecules associated with the mesenchymal phenotype has been 
detected. The expression of vimentin and loss of apical-basal polarization is a characteristic 
change of cells undergoing EMT (Peinado et al., 2007).  
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2.2.4 Proteolytic enzymes in bladder cancer invasion 
Proteolytic activity is of fundamental importance for the development, growth and 
maintenance of homeostasis of all the tissues in any organism. In each particular tissue, the 
activity of proteolytic enzymes is regulated at different levels, both at gene expression, 
transcriptional regulation and by specific endogenous inhibitors (Durkan et al., 2003; Kumar 
et al., 2010). In addition, these enzymes can activate each other through a mechanism 
cascade that also regulates their activity. The genetic instability of tumor cells leads to 
alterations in the genes encoding proteolytic enzymes and/or their inhibitors, which lead to 
an increased proteolytic activity in the tumor. It is well documented that proteolytic 
enzymes are involved in the process of invasion and metastasis. Matrix metalloproteinases 
(MMPs),cathepsins (B, L) and urokinase-type plasminogen activator (uPA) are the three 
main groups of enzymes described in the process of tumor invasion.  
MMPs, of which several isoforms are known, have a major role in matrix destruction and 
are involved in metastasis by mediating basement membrane destruction and angiogenesis 
(Kim et al., 2004). Of all known isoforms, MMP-2 and MMP-9 are strongly associated with 
invasion in bladder cancer (Eissa et al., 2007; Papathoma et al., 2000). 
Cathepsins have also been involved in cancer invasion. Cathepsin B (CB) is one of the most 
abundant lysosomal cysteine proteinase in mammalian tissue. It is synthesized as a 
glycosylated zymogen named pro-CB and subsequently converted to an active form of 33 
kDa or 27-29 kDa.  CB has an important role in the lysosomal degradation of proteins and is 
also involved in the degradation of the extracellular matrix in neoplastic and inflammatory 
diseases. Particularly, results from our laboratory have shown that the high expression of 
the active form of CB in transitional bladder tumors is associated with worse prognosis 
factors such as invasiveness and high histological grade (Eiján et al., 2003). 
The proteolytic activity of uPA is a system regulated by urokinase, its specific receptor 
uPAR and the specific plasminogen activator inhibitor 1 (PAI-1). This system plays a major 
role in tumorigenesis, tumor progression, tumor invasion and metastasis formation. It is 
generally assumed that the pro-malignant effect of the uPA-uPAR system is mediated by 
increased local proteolysis, thus favoring tumor invasion, as well as by the pro-angiogenic 
effect (Binder et al., 2008). Consistent with this activity it has been shown, in a rat orthotopic 
model, that intravesical administration of PAI-1, which inhibits uPA activity in tumors, 
reduces the growth and progression of bladder cancer (Chen et al., 2009). 
2.2.5 Orthotopic mouse bladder cancer invasion model 
Certain fundamental properties of metastatic cells such as migration and invasion can be 
studied in the laboratory using tumor cell cultures. Using various tools of genetic 
engineering, genes that encode molecules that emit fluorescence (green fluorescent protein), 
bioluminescent molecules (luciferase) or molecules with color (beta galactosidase) can be 
introduced into the cell. This technique is known as reporter gene and has allowed the 
analysis of molecular processes at the level of cell groups or isolated cells (Ghajar et al., 2008; 
Menon et al., 2009). In vitro experiments have also been useful to shed light on genes that 
might be involved in certain steps of the metastatic cascade. So, the use of genetic and 
pharmacological methods has shown that the expression of certain genes facilitate the 
assembly of new tumor blood vessels, tumor cells out of circulation and the passage of 
circulating tumor cells through the pulmonary capillaries to grow lung metastases (Gupta et 
al., 2007; Valastyan et al., 2009). However, in vitro models allow a simple analysis and do not 
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always allow evaluating interactions with the tumor microenvironment. It is therefore 
important to develop animal models to analyze the factors associated with tumor 
progression (Bos et al., 2010). To this end, we have added the advances in multiphoton 
intravital microscopy, which allows observing the in vivo behavior of tumor cells labeled 
with green fluorescent protein in the process of invasion and metastasis (Condeelis et al., 
2003). 
There are only few useful animal models to study the processes of invasion and metastasis. 
Dinney et al. have designed an orthotopic murine model with different degrees of invasion. 
To this end, they seeded human 253J cells into the bladder wall of immunodeficient mice 
(nude) and then selected subpopulations of the parental line by in vivo reimplantation in the 
bladder. After five serial passages, tumors were more tumorigenic and showed metastatic 
capacity (Dinney et al., 1995). These authors observed that these variants had a tumoral 
abnormal  karyotype, increased expression of molecules such as epidermal growth factor 
receptor (EGFR), interleukin 8 (IL-8) and MMP-9, and also observed an increased 
anchorage-independent growth and increased capacity to migrate in Matrigel ® (trade name 
of a protein mixture secreted by mouse sarcoma cells Engelbreth-Holm-Swarm), commonly 
used in the study of invasive and migratory behavior of tumor cells in contact with 
extracellular matrix components.  
This is a xenogeneic model in which it is possible to study the changes experienced by the 
tumor cells to acquire their invasive and metastatic phenotype. While this is an ingenious 
and very useful model, the fact that it is an immunodeficient mouse slightly restricts the 
applicability of the model. 
 
 
Fig. 6. MB49-I cell line obtained by successive in vivo passages of primary tumor obtained 
by inoculation of the MB49 bladder tumor cell line. The orthotopic inoculation in bladder of 
MB49 or MB49-I generates non-muscle invasive or muscle invasive tumors respectively. 
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In our laboratory, following the methodology of Dinney, but with subcutaneous inoculation, 
we developed a syngeneic murine model that reproduces the human pathology in terms of 
invasion status. A single cell suspension of the MB49 cell line was inoculated 
subcutaneously in the flank of syngeneic C57BL/6J mice. After 24 days, tumors were 
surgically removed and 2-mm tumor pieces were transplanted by trocar into the left flank of 
mice. This process was repeated 13 consecutive times. We found that the growth rate was 
increased in transplants #6 to #10 and then became stable. Therefore, primary culture from 
transplant #13 was carried out and the cell line originated was named MB49-I. The 
orthotopic inoculation of MB49 or MB49-I in the bladder generates non-muscle invasive or 
muscle invasive tumors respectively (Figure 6).  
This new line has more aggressive characteristics. The MB49-I cell line has higher activity of 
the MMP-9, uPA and CB as well as increased in vitro invasion of Matrigel ®. Given the 
association of these enzymes with bladder cancer progression, our model has close 
similarities to human disease. The histopathological study in vivo showed results consistent 
with in vivo tests. Intravesical inoculation of MB49 cells was able to develop tumors without 
muscle invasion. By contrast, inoculation of the MB49-I cell line generated carcinoma with a 
disorganized structure and larger tumors with cellular atypia, muscle layer invasion and 
lung metastasis (Figure 7).  
 
 
Fig. 7. Haematoxylin-eosin staining for bladder tumors. A: It can see two formations of a 
tumor of bladder MB49: one sessile and one pedunculated,  which do not invade the muscle 
wall. B: MB49 the polypoid formation is magnified 400X. C: image of a tumor MB49-I, we 
observe a large tumor invading the muscular layer. D: MB49-I bladder tumor with higher 
magnification, where the tumor cells are intermingled with the muscle fibers. 
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Cellular plasticity is a fundamental process during tumor progression. It is now accepted 
that epithelial-mesenchymal transition is associated with tumor progression. A mark of this 
transition is the loss of cytokeratin and an increase in vimentin. MB49-I has not only 
morphological diversity, but also decreased cytokeratin and increased vimentin expression 
in vitro and in vivo. 
Since both the xenogeneic and syngeneic models described here resemble human bladder 
cancer, they could be useful to study tumor progression, tissue remodeling, and invasive 
and metastatic processes, and to assay anti-invasive and metastatic agents.  
3. Conclusions 
Since animal models can reproduce the tumor-host interactions, performing studies using 
these models is a mandatory step to translate from basic research to the clinic. Taking into 
account that animal experiments are performed to obtain an improvement for human-
health, but must generate a reduced impact on the animals, these experiments should be 
made according to international rules of bioethics. To accomplish the maximum welfare of 
the animal, every protocol, indicating the justification of each experiment and the 
methodology to be used, must be approved by the institutional ethics committee for the use 
of laboratory animals.   
The ideal animal model should meet all the characteristics of the human pathology, such as 
growth parameters, histology, evolution and metastatic dissemination. However, in the 
practice, the ideal model does not always have a complete similarity. The researcher must 
thus decide which model best fits the question to be answered. Alternatively, the researcher 
can design his/her own model that most closely approaches the point of interest.  
The generation of transgenic animals is one of the most developed branches in animal 
models. Technical refinements have allowed generating genetically modified mice either 
stable or conditional, making them a valuable tool.  
Animal models that mimic human bladder cancer in terms of invasion have also been 
developed. The use of successive transplants of tumors derived from a cancer cell line can 
generate invasive bladder tumors. Both the syngeneic and xenogenic invasive models of 
tumor are useful in the study of tumor progression. Finally, it is important to note that for a 
better understanding of the tumor mechanism and the relationship with the host, the best 
models are those, like MB49-I, in which the tumor is inoculated in an orthotopic site. 
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